The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Development and independent validation of a predictive gene expression signature based on RB1, PTEN, and TP53 in patients with metastatic hormone-sensitive metastatic prostate cancer (mHSPC).
 
Oscar Reig Torras
Honoraria - BMS; Ipsen; Pfizer
Consulting or Advisory Role - Eisai
Speakers' Bureau - Bayer; Bristol-Myers Squibb; Ipsen; Janssen-Cilag; Pfizer; Sanofi
Travel, Accommodations, Expenses - Ipsen
 
Marta Garcia de Herreros
No Relationships to Disclose
 
Natalia Jiménez
No Relationships to Disclose
 
Caterina Aversa
Research Funding - Janssen (Inst)
Travel, Accommodations, Expenses - Ipsen; Janssen; Janssen
 
Mercedes Marín-Aguilera
Employment - Reveal Genomics
 
Laura Ferrer Mileo
No Relationships to Disclose
 
Leonardo Rodriguez-Carunchio
No Relationships to Disclose
 
Isabel Trias
No Relationships to Disclose
 
Albert Font Pous
Consulting or Advisory Role - Astellas Pharma; Janssen; Sanofi
 
Alejo Rodriguez-Vida
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Janssen; MSD; Pfizer; Roche; Sanofi
 
Montserrat Domenech-Santasusana
No Relationships to Disclose
 
Mariona Figols
Consulting or Advisory Role - Ipsen; Pfizer
Travel, Accommodations, Expenses - Merck
 
Miguel Ángel Climent
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai Europe; EUSA Pharma; Ipsen; Janssen; Merck; MSD Oncology; Novartis; Pfizer; Pierre Fabre; Roche; Sanofi
Consulting or Advisory Role - Astellas Pharma; Bayer; Bristol-Myers Squibb; Celgene; Eisai; EUSA Pharma; Janssen Oncology; Janssen-Cilag; Merck; MSD Oncology; Pfizer; Roche/Genentech; Sanofi
Travel, Accommodations, Expenses - Ipsen; Janssen; Merck; Pfizer; Roche
 
Sara Cros Costa
Honoraria - GlaxoSmithKline; PFIZER; ROCHE; SANOFI
Consulting or Advisory Role - GlaxoSmithKline; Pfizer; SANOFI
Research Funding - Janssen; Pfizer
Travel, Accommodations, Expenses - GlaxoSmithKline; Roche
 
Isabel Chirivella
No Relationships to Disclose
 
Daniel Herrero Rivera
Honoraria - Pfizer
 
Daniel Jiménez-Peralta
No Relationships to Disclose
 
Enrique Gonzalez -Billalabeitia
No Relationships to Disclose
 
Joan Carles
Consulting or Advisory Role - Advanced Accelerator Applications/Novartis; Astellas Pharma; AstraZéneca; Bayer; Bristol-Myers Squibb; Johnson & Johnson/Janssen; MSD Oncology; Pfizer; Roche; Sanofi
Speakers' Bureau - Astellas Pharma; Bayer; Johnson & Johnson
Research Funding - AB Science (Inst); Aragon Pharmaceuticals (Inst); Arog (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AVEO (Inst); Bayer (Inst); Blueprint Medicines (Inst); BN ImmunoTherapeutics (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb International Corporation (BMS) (Inst); Clovis Oncology (Inst); Cougar Biotechnology (Inst); Deciphera; Exelixis (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Janssen-Cilag International NV (Inst); Karyopharm Therapeutics (Inst); Laboratories Leurquin Mediolanum (Inst); Lilly (Inst); Medimmune (Inst); Millenium Pharamceuticals (Inst); Nanobiotix (Inst); Novartis Farmacéutica SA (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Roche (Inst); Sanofi Aventis GmbH (Inst); SFJ Pharmaceuticals Group (Inst); Teva (Inst)
Travel, Accommodations, Expenses - AstraZeneca; BMS; Ipsen; Roche
 
Begoña Mellado-Gonzalez
No Relationships to Disclose